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Vascular endothelial growth factor (VEGF)-A inhibitors exhibit unseen high responses and toxicity in recurrent epithelial ovarian
cancer suggesting an important role for the VEGF/VEGFR pathway. We studied the correlation of VEGF signalling and AKT/mTOR
signalling. Using a tissue microarray of clinical samples (N¼86), tumour cell immunohistochemical staining of AKT/mTOR downstream
targets, pS6 and p4E-BP1, together with tumour cell staining of VEGF-A and pVEGFR2 were semi-quantified. A correlation was found
between the marker for VEGFR2 activation (pVEGFR2) and a downstream target of AKT/mTOR signalling (pS6) (R¼0.29;
P¼0.002). Additional gene expression analysis in an independent cDNA microarray dataset (N¼24) showed a negative correlation
(R¼ 0.73, Po0.0001) between the RPS6 and the VEGFR2 gene, which is consistent as the gene expression and phosphorylation of
S6 is inversely regulated. An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites
(w
2, P¼0.002) and reduced overall survival of cisplatin–taxane-based patients with serous histology (N¼32, log-rank test, P¼0.04).
These data propose that VEGF-A signalling acts on tumour cells as a stimulator of the AKT/mTOR pathway. Although VEGF-A
inhibitors are classified as anti-angiogenic drugs, these data suggest that the working mechanism has an important additional modality
of targeting the tumour cells directly.
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In the Western world, ovarian cancer has the highest mortality rate
among gynaecological malignancies (Jemal et al, 2008). There is an
unmet need for novel targeted therapies that can improve current
treatment outcomes (Kelland, 2005). In early clinical studies,
remarkable activity of single agents targeting VEGF-A has been
observed (Martin and Schilder, 2007). The working mechanism of
these anti-VEGF-A inhibitors is believed to be inhibition of
angiogenesis as VEGF-A is a critical and major step in angio-
genesis (Ferrara, 2004, 2005). As single agent, bevacizumab,
the monoclonal humanised antibody against VEGF-A, yielded
response rates of 15.9 and 21.0% in refractory ovarian cancer
patients in phase II trials and is currently the subject of phase III
trials (Burger, 2007; Burger et al, 2007; Cannistra et al, 2007).
In comparison, although it is difficult to compare different phase II
trials, the observed response rate with single-agent bevacizumab
was only 3.3% in metastatic colorectal cancer (Giantonio et al,
2007). In a metastatic renal cell cancer phase II trial, the response
of single-agent high-dose bevacizumab was found to be 10.3%,
whereas in metastatic breast cancer the total objective response
rate was 6.7% (Cobleigh et al, 2003; Yang et al, 2003). In addition
to its apparently different antitumoural effect, the highest
incidence of gastrointestinal perforations (6%) is observed
in ovarian cancer compared with the overall incidence of 1.7%
in patients who receive bevacizumab for malignancies (Badgwell
et al, 2008). In one phase II trial, the incidence was even found to
be 11% (Cannistra et al, 2007).
The distinct response rates and toxicity observed indicate
that VEGF-A signalling may have different mechanisms
depending on the tumour type studied and also that there is
a particular prominent role for VEGF-A in ovarian cancer.
Therefore, further research of VEGF-A mechanisms in ovarian
cancer is warranted. Several reports have identified the VEGFR2,
also known as KDR, on epithelial tumour cells, including its
localisation in ovarian cancer cells (Masood et al, 2001; Stewart
et al, 2003; Inan et al, 2006). In vitro studies have suggested
an autocrine growth factor function of VEGF-A/VEGFR2
signalling (Masood et al, 2001; Inan et al, 2006). However, the
clinical importance of these non-endothelial VEGF receptors
remains elusive. In this study, we assessed the VEGF-A/VEGFR2
pathway in human ovarian carcinoma tissue in terms of VEGF
expression, VEGFR2 expression, and its activation status. As
VEGFR2 exerts its function through the PI3K/Akt/mTOR signal-
ling pathway in endothelial cells (Figure 1), the activation status
of VEGFR2 was studied by determining phosphorylation of
VEGFR2 itself together with phosphorylation of down-
stream targets of mTOR. In addition, the association of VEGFA,
VEGFR2 and their activation status with clinical outcome were
established.
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Patient and tissue selection
Formalin-fixed paraffin-embedded (FFPE) epithelial ovarian cancer
tissues were collected retrospectively from 1999 to 2004 in the
St Augustinus hospital in Belgium using pathology archives. The
local IRB reviewed and approved the study. Clinical parameters
were obtained from patients’ medical files, that is, FIGO stage,
grade, age at the time of diagnosis, date and type of surgery,
histology, presence of ascites and treatment modalities. Remaining
tumour load after debulking, which was not consistently recorded,
was not included. The patients’ characteristics are listed in Table 1
and the biopsy characteristics in Figure 2. Median age of the
patients was 61.6 years (27–92 years). Twelve patients did not
receive systemic treatment. The majority received platinum in
combination with taxane chemotherapy (N¼33). Other treatments
included carboplatinum monotherapy (N¼1), carboplatinum–
cyclofosfamide (N¼5) and cyclophosphamide–adriamycin–
cisplatin (N¼2).
Tissue samples from 89 patients were included on the tissue
microarray (TMA). Primary untreated ovarian lesions were
available in 86 out of 89 patients, whereas in the remaining three
subjects, only an untreated peritoneal biopsy was available
(Figure 2). In 49 out of 89 patients, metastatic (peritoneal or
omental) lesions were surgically removed at the same time by
laparotomy, either during primary debulking or during interval
debulking. Tissues were also collected from patients who had
neoadjuvant chemotherapy before debulking surgery. In these
patients, (16 out of 89) there was tissue from baseline biopsy and
tissue from debulking surgery, which were all performed after
three cycles of taxane–platinum chemotherapy.
Tissue microarray
Using the Beecher Instruments Tissue Arrayer (Beecher
Instruments, Silver Springs, MD, USA) a TMA was constructed.
Haematoxylin eosin (HE) staining for each paraffin block was
reviewed and three representative areas were selected on the HE
slide. From each paraffin block, three sample cores were taken,
each of which corresponded to the earlier selected areas on the
HE slide. Five-mm slides were cut from the TMA for immuno-
histochemical staining.
Immunohistochemistry
Immunohistochemistry was performed on consecutive slides for
pS6, p4E-BP1, pVEGFR2(Tyr996) (Cell Signalling Technologies,
Beverly, MA, USA; #2211, #2474, #9451), pVEGFR2(Tyr951) (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA; #sc-16628-R) and
VEGF-A (Dako Corp., Glostrup, Denmark, VG1clone M7273).
After deparaffinisation and rehydration, antigen retrieval was
performed using a citrate buffer (pH6.0) (pS6, p4E-BP1, VEGF-A)
or an EDTA buffer (pH9.0) (pVEGFR2) at sub-boiling temperature
for 30min. After 30min of cooling on bench top, sections were
treated with 1% H2O2 and then incubated with the primary
antibodies for 1h at room temperature at 1:200 dilution for pS6,
1:50 for p4E-BP1, 1:100 for pVEGFR2(Tyr996) and 1:150 for
pVEGFR2(Tyr951). Binding of antibodies was visualised using
Envisionplus dual link system (Dako Corp.) and 3,3-diaminoben-
zidine for 10min. Sections were counterstained with Mayer’s
haematoxylin. For the VEGF-A staining, a 1:800 dilution with 1-h
incubation was used with the Catalyzed Signal Amplification kit
(CSA kit Dako Corp.). Ki67 staining was performed as described
earlier (Van den Eynden et al, 2007). A breast carcinoma and
melanoma (for VEGF-A, pVEGFR2), and a prostate cancer
specimen (for pS6, p4E-BP1) served as positive controls. Negative
controls were run by omitting the primary antibody. All the
staining was done on the Dako autostainer (Dako Corp.).
Quantifictation of the staining
The H-score, that is, the percentage of cells staining positive
multiplied by an intensity score (0–3), was used for
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Figure 1 In endothelial cells, after activation, VEGFR2 is able to stimulate the AKT/mTOR signalling pathway through PI3K. More downstream 4E-BP1,
P70S6K1 and S6 are phosphorylated. The mTORC2 complex (insensitive to rapamycin/FKBP12) has been shown to be an activator of AKT. The mTORC1
complex is sensitive to rapamycin (sirolimus) or derivates (everolimus, temsirolimus and deforolimus).
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2007). The semi-quantification was performed by two independent
observers who were blinded from clinical data. As three cores were
taken from a single paraffin block, the average H-score over the
three cores was used for further analysis. Ki67 staining was
quantified with a proliferation index (number of Ki67 positive
proliferating tumour cells per 100 tumour cells) using 200 counted
cells per tissue core.
Statistical and survival analysis
All statistical analyses were performed using SPSS 13.0 (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism 3.03 (GraphPad Software,
Inc., La Jolla, CA, USA) statistical packages. Marker correlation
analysis of H-scores was performed using the Spearman correla-
tion coefficient. For survival analysis, only those patients who had
taxane–platinum first line chemotherapy and serous papillary
histology were selected (N¼32). For this, the expression of
pVEGFR2 and pS6 was dichotomised in high or low category using
the median expression as a cutoff value. Wilcoxon matched paired
testing was performed on the H-scores if primary ovarian tissue as
well as a metastatic lesion was available from the same patient, at
the same time of surgical excision (N¼49). Similarly, Wilcoxon
matched paired testing was conducted if the tissue, before chemo-
therapeutical treatment and after neoadjuvant taxane–platinum
chemotherapy, was available from the same patient (N¼16).
In silico gene expression analysis
Normalised gene expression data was derived from a molecular
profiling study described earlier, including 24 independent
untreated primary ovarian cancer lesions, using 18K cDNA
microarray (Helleman et al, 2006; Erasmus MC, Rotterdam, The
Netherlands). The expression values of RPS6 (coding for S6
protein), EIF4EBP1 (coding for 4E-BP1 protein) and VEGFR2/KDR
were analysed for correlation studies. The mean of duplicate
analyses was used. In addition, gene expressions for RPS6 and
EIF4EBP1 were derived from a publicly available gene expression
Table 1 Summary of clinical data (N¼89 patients)
N pVEGFR2(Tyr996) pVEGFR2(Tyr951) pS6 p4E-BP1 VEGF-A Ki67
FIGO I 19 270 275 20 100 200 18.5
FIGO II 4 285 100 45 125 150 20.0
FIGO III 56 210 100 20 90 200 19.0
FIGO IV 10 300 180 150 160 200 18.0
NS NS NS NS NS NS
Grade 1 20 300 200 30 90 150 18.5
Grade 2 27 180 80 15 80 200 12.0
Grade 3 42 300 100 20 160 200 21.0
P¼0.06 NS NS P¼0.085 NS NS
Serous papillary 47 270 180 20 80 200 17.0
Mucinous 4 195 250 20 95 150 29.0
Endometrioid 23 210 80 25 160 100 23.5
Clear cell 10 195 50 40 95 100 4.5
NS NS NS NS P¼0.0002 P¼0.095
Total 89 240 (0–300) 160 (0–300) 20 (0–300) 100 (2–300) 200 (0–300) 19.0 (0–66)
Median H-scores are reported. P-values (Kruskal–Wallis tests) are reported in case of significance (Po0.05) or in case of trend (Po0.10). After Bonferroni correction for
multiple testing Po0.008 was considered significant.
N=89
Only peritoneal
biopsy
N=3
Ovarian biopsy
N=13
Primary
debulking
N=73
Neoadjuvant
taxane–
platinum
N=16
Interval
debulking
N=16
Adjuvant taxane–platinum
+ available follow-up N=17
Other type adjuvant chemotherapy N=8
No adjuvant treatment N=12
No follow-up data N=36
Available primary ovarian lesions N=86/89
Available comcomitant untreated vs treated lesions N=16/89
N=33
Survival
analysis
Figure 2 Schematic overview of patients included in the study.
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somnibus dataset of Mus musculus prostate samples before and
after (12 and 48h) mTOR inhibition with the RAD001 compound.
These samples were processed using Affymetrix GeneChip Mouse
Expression Set 430 Array MOE430A (Affymetrix Inc., Santa Clara,
CA, USA). Microarrays were background adjusted, normalised,
summarised and
2log transformed according to GC Robust
A
B
C
D
E
50m 50m
50m 50m
50m 50m
50m 50m
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Figure 3 (A–E) Serial slides with immunohistochemical staining for pVEGFR2(Tyr951) (A), pVEGFR2(Tyr996) (B), pS6 (C), p4E-BP1 (D), VEGF-A
(E) of an ovarian cancer specimen. Note that there were locally places in which there was more prominent staining for pVEGFR2 with a concomitant
expression of the ribosomal protein pS6.
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of the RPS6 gene and two were available for EIF4EBP1 gene.
Samples were divided into three groups: placebo treated (N¼18),
12h RAD001 treated (N¼11) and 48h RAD001 treated (N¼9).
One-way ANOVA tests with additional Student–Newman–Keul’s
post test (if Po0.05) were performed.
RESULTS
Immunostaining and marker correlative studies
An example of staining of pVEGFR2(Tyr996), pVEGFR2(Tyr951)
pS6, p4E-BP1 and VEGF-A is shown in Figure 3. A summary of the
staining H-scores is listed in Table 1, whereas the correlations are
presented in Figure 4. VEGF-A expression is most prevalent in
serous papillary tumours (P¼0.0002). The staining of the VEGFR2
phosphorylated at tyrosine residue 996 or 951 was found to be
cytoplasmic, nuclear and/or membranous. There was a correlation
(R¼0.70, Po0.00001) between both pVEGFR2 staining, namely
the VEGFR2 phosphorylated at tyrosine residue 951 and that
phosphorylated at tyrosine residue 996, using different antibodies
that were raised to detect different epitopes. The staining patterns
for pS6, p4E-BP1 and nuclear ki67 staining were similar to the
reports described earlier (Van den Eynden et al, 2005; Castellvi
et al, 2006; Rojo et al, 2007). A predominantly often granular
staining of VEGF-A was observed in the tumour cell cytoplasm as
well in the stromal compartment of the tumour.
For correlations, (Figure 4) primary untreated ovarian lesions
(N¼86) were included. Correlations between pVEGFR2(Tyr996)
and downstream markers for the AKT/mTOR signalling pathway
(pS6 and p4E-BP1) were found for pVEGFR2(Tyr996) and pS6
(R¼0.29, P¼0.002), and also for pVEGFR2(Tyr996) and p4E-BP1
(R¼0.18, P¼0.05).
When studying only metastatic lesions (N¼59), the correlation
of pVEGFR2(Tyr996)–pS6 was even more pronounced (R¼0.44,
Po0.0001), whereas there was no correlation between pVEGFR2
(Tyr996)–p4E-BP1 (R¼0.12 P¼0.25). Interestingly, the expres-
sion of pVEGFR2(Tyr996) was found to be significantly lower in
metastatic lesions when compared with primary ovarian lesions
surgically removed at the same time (median H-score¼90, range
(0–300) vs 150, range (0–300); P¼0.01, N¼49). The expression of
pS6 and p4E-BP1 was not significantly different.
The tissue microarray also contained samples pre- and post-
neoadjuvant chemotherapy. Although the study was retros-
pective, the administration of the neoadjuvant chemotherapy was
according to hospital protocol and uniform; after three cycles of
taxane–platinum chemotherapy an interval debulking surgery
procedure was performed. Sixteen patients were eligible
for analysis as pre- and post chemotherapy FFPE tissues were
available (Figure 2). pVEGFR2(996) expression levels after
chemotherapy were lower compared with the initial untreated
biopsy (median H-score¼50, range (0–300) vs 300, range
(120–300); Po0.0001). For the pS6 and p4E-BP1 expression there
was no significant difference found. Again, the correlation of
pVEGFR2(Tyr996) and pS6, and pVEGFR2(Tyr996) and p4E-BP1
was present in lesions treated after chemotherapy (R¼0.44,
P¼0.002–R¼0.27 P¼0.054).
0.22 NS NS NS NS Ki67
1 0.21 0.20 0.18 NS p4E-BP1
0.21 1 0.21 0.29 NS pS6
0.20 0.20 1 0.70 0.29
pVEGFR2
(951)
0.18 0.29 0.70 1 0.25
pVEGFR2
(996)
NS NS 0.29 0. 25 1 VEGF-A
p4E-BP1 pS6
pVEGFR2
(951)
pVEGFR2
(996)
VEGF-A
R Spearman
Correlation
Coefficient
Correlation with P<0.05
No significant correlation
Correlation with P<0.01
Perfect correlation
Figure 4 A summary of immunohistochemical correlations.
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Figure 5 The
2log relative gene expression correlations using an
independent dataset of epithelial ovarian cancer samples. The RPS6 gene
was significantly well correlated with the relative expression of VEGFR2.
(vertical bars show 95% CI).
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Next, the observed immunohistochemical correlation of pVEGFR2
and pS6 was studied in silico at a gene expression (mRNA) level
from cDNA microarrays of 24 ovarian cancers from the Erasmus
MC centre (Helleman et al, 2006). Relative gene expressions were
correlated between the VEGFR2 gene and the RPS6 and EIF4EBP1
genes. There was a highly significant, but negative, correlation
between the VEGFR2 and RPS6 (R¼ 0.73; Po0.0001), whereas
there was no correlation with EIF4EBP1 (Figure 5). This negative
correlation is compatible with the findings that the gene
expression of S6 and its phosphorylation status is inversely
regulated.
Phosphorylation of the ribosomal protein S6 is completely
inhibited after mTOR inhibition, thus protein expression of pS6 is
expected to decrease (Tabernero et al, 2005). In silico analyses
(Affymetrix microarray data from prostate of Mus musculus
treated with mTOR inhibitor RAD001) show that this downstream
marker of the AKT/mTOR signalling pathway is upregulated after
mTOR inhibition. A significant, apparently time dependant,
increased gene expression after mTOR inhibition of the gene
RPS6 could be seen, whereas there was no significant change for
EIF4EBP1 (Figure 6).
Survival analysis
The expression of pS6 and VEGFR2(Tyr996) was dichotomised
using the median expression as a cutoff value. Patients were
divided into three groups: (1) patients with a high expression of
pS6 and pVEGFR2(Tyr996) (N¼8), ‘activated pathway’, (2)
patients with a combined low expression of pS6 and pVEGFR2
in the tumour (N¼9) and (3) the intermediate group, in which
only one out of two markers had high expression (N¼15).
A significant reduced survival was found in patients who had a
combined high expression of pVEGFR(Tyr996) and pS6 (log-rank
test, P¼0.041) (Figure 7). In an exploratory multivariate
analysis using Cox Proportional Hazard regression model correcting
for FIGO stage and grade, this significance is retained (P¼0.048, HR
2.90, 95% CI (1.01–7.97)) and FIGO staging was also found to
be a independent prognostic factor (P¼0.050, HR 1.99, 95% CI
(0.89–4.47)).
A combined high expression of pVEGFR2(Tyr996) and pS6 was
significantly associated with the presence of ascites (87.5%, N¼7/8),
whereas in patients with a low expression of both markers, the
presence of ascites was only 11.1% (N¼1/9). In the intermediate
group there was ascites in 40.0% (N¼6/15) (P¼0.002; w
2 test for
linear by linear association).
DISCUSSION
Using human ovarian cancer samples, a correlation was observed
between the activated status of the VEGFR2 and downstream
markers of the AKT/mTOR signalling pathway, pS6 and p4E-BP1
protein. Especially, the correlation of pVEGFR2(Tyr996) and pS6
was found to be the most noteworthy correlation between VEGF-A
signalling and AKT/mTOR signalling. For these two markers,
besides the H-score correlations that were observed, a correlation
could also be seen in heterogenic staining areas of some tumour
samples, that is, places where pVEGFR2-positive cells also clearly
stained more positive for pS6 (Figure 3). Two antibodies were used
in this study for pVEGFR2. Mainly, the results of pVEGFR(Tyr996)
were reported because pVEGFR2(Tyr996) seems to be a better
potential marker for bevacizumab efficacy (Wedam et al, 2006).
Similarly, for markers of the AKT/mTOR signalling pathway
two antibodies were selected also, with a preference for pS6, as
there is evidence that S6 is more specifically regulated by mTOR
(Tabernero et al, 2008). However, p4E-BP1 was also chosen
because it has been shown to be a hallmark protein downstream of
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Figure 6 After 48h RAD001 administration, prostate tissue showed a significant increase of normalised gene expression for RPS6 compared with 12h
(Po0.01—
2log mean channel count increase of þ0.28 95% CI (0.08–0.48)) and placebo-treated mice (Po0.001—
2log mean channel count increase of
þ0.35 95% CI (0.17–0.53)), This effect was not observed for the expression of EIF4EBP1 (n.s.).
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Figure 7 Kaplan–Meier survival curve (N¼32 patients). Baseline
expression of pS6 and pVEGFR2 were dichotomised into a high (þ)
and low ( ) category using the median expression H-score value (log-rank
test, P¼0.041).
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smTOR that is associated with grade and survival in ovarian cancer
as well as in breast cancer (Castellvi et al, 2006; Rojo et al, 2007).
Gene expression analysis showed that, after mTOR inhibition,
the gene expression of S6 changed, whereas for 4E-BP1 it did not.
Although the change fold (o2) was minimal, it was an apparently
time dependant, clearly significant change. Here, the negative
correlation of VEGFR2 and RPS6, is compatible with the finding
that the phosphorylation of S6 is inversely regulated with its gene
expression. These data are therefore indirectly confirmative for the
immunohistochemical findings that showed a positive correlation.
Given our current knowledge, there are many uncertainties and
it is too early to rely completely on biomarkers for clinical usage.
To fully appreciate the value of biomarkers, extensive translational
research in considerable number of patients, are needed (Sleijfer
and Wiemer, 2008).
Nevertheless, our findings strongly suggest activation of the
VEGFR2 pathway in ovarian cancer. Consistent with our data,
earlier, a similar study with human samples has shown the
expression of the VEGFR2 to be been associated with the activation
of the signal transducers and activators of transcription pathway,
another intracellular signalling pathway of VEGFR2 (Chen et al,
2004). The most likely way by which this receptor is activated is
through binding of its ligand, VEGF-A. Platelets are a major source
of VEGF-A that is targeted by bevacizumab (Verheul et al, 2007).
As the ovarian tumour cells are known to excrete the endothelial
growth factor VEGF-A as well, this suggests an autocrine/paracrine
growth factor function of VEGF-A in ovarian cancer through the
AKT/mTOR signalling pathway. The dual expression of VEGFR/
VEGF-A in ovarian cancer, as well as in other types of cancers,
suggests that the activation of tumour cell signalling pathways by
VEGF-A might be an autocrine mechanism that could also be
present in other tumours such as colorectal or breast carcinoma
(Masood et al, 2001; Price et al, 2001; Chen et al, 2004; Fan et al,
2005; Wedam et al, 2006).
Anti-angiogenesis with agents such as bevacizumab are believed
to act through blocking VEGF-A action on endothelial cells. The
unseen antitumoural effects observed after bevacizumab treatment
in refractory- and platinum-resistant ovarian cancer patients
indicate that these responses possibly are not only caused by
inhibition of angiogenesis. We hereby show that a presumed
activated VEGFR2/AKT/mTOR pathway, that is endothelial cell
independent, was found to be associated with significantly reduced
survival. Although the study cohort was small, without searching
for a cutoff value, significance could be shown. The fact that this
activated pathway was associated with increasing incidence of
ascites is maybe not surprising. VEGF-A, formerly know as
vascular permeability factor, has been found to play an important
role in the accumulation of pleural or peritoneal effusions (Senger
et al, 1983; Nagy et al, 1993, 1995; Yeo et al, 1993; Masood et al,
2001). Also, in preclinical studies, the bevacizumab murine
precursor was more an inhibitor of ascites formation than that it
was an inhibitor of tumour growth (Mesiano et al, 1998).
The observed correlation between the VEGF-A pathway and the
AKT/mTOR pathway has potential clinical importance. mTOR
inhibitors gain much clinical interest as an antitumoural agent,
such as in renal cell carcinoma (Hudes et al, 2007). For ovarian
cancer, clinical trials are ongoing. Up to date, there is only
preclinical data available to suggest that mTOR inhibition might be
beneficial in epithelial ovarian cancer. Altomare et al, 2004 studied
the phosphorylation of AKT on ovarian cancers in a tissue
microarray and found overexpression of p-AKT on 68% of the 31
tumours. Mabuchi et al, 2007a, 2007b found that mTOR inhibition
by RAD001 reduced human ovarian cancer cell proliferation,
enhanced cisplatin-induced apoptosis and prolonged survival in
an ovarian cancer xenograft model. They also showed that RAD001
inhibited the expression of HIF 1 alpha and VEGF-A in vitro cell
lines. Interestingly, dual targeting of VEGF-A and mTOR in
ovarian caner xenograft models has shown an additive, if not
synergistic, antitumoural effect with survival benefit. Additionally,
the combination therapy was able to reverse the accumulation of
ascites, which is in agreement with our findings (Huynh et al,
2007).
Anti-VEGF treatments in ovarian cancer seem to be very active,
although at this moment, the associated toxicity is worrisome.
mTOR inhibitors might have the potential of avoiding these
problems Taking our data into consideration, suggestive of an
autocrine VEGF-A loop through the AKT/mTOR signalling path-
way, this adds preclinical rationale for mTOR inhibition in the
management of ovarian cancer. The results of the GOG phase II
trial, which is ongoing, will reveal if temsirolimus has single-agent
activity in recurrent/refractory patients.
We started a multicentre prospective study in 2006 with the aim
of standardised collection of snap frozen human ovarian cancer
tissues. Similar experiments will reveal if our present findings can
be confirmed. We will try to further elucidate the interaction
between both the pathways at a more detailed gene expression
level. In any future clinical trials, we emphasise the necessity of
tissue/ascites sampling for translational and biomarker studies.
In conclusion, we propose that the working mechanism of anti-
VEGF treatments in epithelial ovarian cancer is not only anti-
angiogenesis. We strongly suggest that these anti-VEGF treatments
are suppressors of epithelial tumour cell growth factor acting as a
surrogate AKT/mTOR signalling inhibitors on tumour cells. Thus,
classifying VEGF trap or bevacizumab as anti-angiogenic agent
does not represent their whole mechanism of action. Based on our
findings, we recommend them as anti-VEGF compounds, at least
in epithelial ovarian cancer.
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